Zynex Announces Partnership To Conduct Business with Veterans Affairs (VA) Medical Centers, the Largest Healthcare Network in the United States
Zynex (NASDAQ: ZYXI) has announced a new partnership to conduct business with Veterans Affairs Medical Centers (VAMCs) across the United States. This collaboration gives Zynex access to the VA's extensive healthcare network, which spends over $112 billion annually on healthcare and serves over 9 million enrolled veterans.
The partnership encompasses 171 VAMCs and over 1,100 outpatient facilities, plus approximately 700 Military Treatment Facilities operated by the Department of Defense. Currently, less than 1% of Zynex's sales come from VAMCs, presenting a significant growth opportunity for the company's non-opioid pain management solutions.
Zynex (NASDAQ: ZYXI) ha annunciato una nuova partnership per condurre affari con i Centri Medici per i Veterani (VAMCs) in tutto gli Stati Uniti. Questa collaborazione offre a Zynex accesso all'ampia rete sanitaria del VA, che spende oltre 112 miliardi di dollari all'anno per la salute e serve oltre 9 milioni di veterani iscritti.
La partnership comprende 171 VAMCs e oltre 1.100 strutture ambulatoriali, oltre a circa 700 Strutture Mediche Militari gestite dal Dipartimento della Difesa. Attualmente, meno dell'1% delle vendite di Zynex proviene dai VAMCs, rappresentando una significativa opportunità di crescita per le soluzioni di gestione del dolore non oppioidi dell'azienda.
Zynex (NASDAQ: ZYXI) ha anunciado una nueva asociación para realizar negocios con los Centros Médicos de Veteranos (VAMCs) en los Estados Unidos. Esta colaboración le da a Zynex acceso a la extensa red de atención médica del VA, que gasta más de 112 mil millones de dólares anuales en atención médica y atiende a más de 9 millones de veteranos inscritos.
La asociación abarca 171 VAMCs y más de 1,100 instalaciones ambulatorias, además de aproximadamente 700 Instalaciones de Tratamiento Militar operadas por el Departamento de Defensa. Actualmente, menos del 1% de las ventas de Zynex provienen de los VAMCs, lo que presenta una oportunidad significativa de crecimiento para las soluciones de manejo del dolor no opioide de la empresa.
Zynex (NASDAQ: ZYXI)는 미국 전역의 재향군인 의료 센터(VAMCs)와 비즈니스를 진행하기 위한 새로운 파트너십을 발표했습니다. 이 협력으로 Zynex는 VA의 광범위한 의료 네트워크에 접근할 수 있으며, 이 네트워크는 연간 1120억 달러 이상을 건강 관리에 지출하고 900만 명 이상의 등록된 재향군인을 지원합니다.
파트너십은 171개 VAMCs와 1,100개 이상의 외래 진료소를 포함하며, 국방부가 운영하는 약 700개 군사 치료 시설도 포함되어 있습니다. 현재 Zynex의 판매 중 1% 미만이 VAMCs에서 발생하며, 이는 회사의 비오피오이드 통증 관리 솔루션에 대한 상당한 성장 기회를 나타냅니다.
Zynex (NASDAQ: ZYXI) a annoncé un nouveau partenariat pour mener des affaires avec les Centres Médicaux des Anciens Combattants (VAMCs) à travers les États-Unis. Cette collaboration donne à Zynex un accès au vaste réseau de soins de santé du VA, qui dépense plus de 112 milliards de dollars par an en soins de santé et sert plus de 9 millions de vétérans inscrits.
Le partenariat comprend 171 VAMCs et plus de 1 100 établissements de soins ambulatoires, ainsi qu'environ 700 installations de traitement militaire gérées par le Département de la Défense. Actuellement, moins de 1 % des ventes de Zynex proviennent des VAMCs, ce qui représente une occasion de croissance significative pour les solutions de gestion de la douleur non opioïdique de l'entreprise.
Zynex (NASDAQ: ZYXI) hat eine neue Partnerschaft zur Zusammenarbeit mit den Veterans Affairs Medical Centers (VAMCs) in den Vereinigten Staaten angekündigt. Diese Zusammenarbeit ermöglicht Zynex den Zugang zum umfangreichen Gesundheitsnetzwerk des VA, das jährlich über 112 Milliarden Dollar für Gesundheitsversorgung ausgibt und über 9 Millionen eingeschriebene Veteranen betreut.
Die Partnerschaft umfasst 171 VAMCs und über 1.100 ambulante Einrichtungen, zusätzlich zu etwa 700 militärischen Behandlungseinrichtungen, die vom Verteidigungsministerium betrieben werden. Derzeit stammen weniger als 1 % der Verkäufe von Zynex aus VAMCs, was eine bedeutende Wachstumschance für die nicht-opioid Schmerzmanagementlösungen des Unternehmens darstellt.
- Access to VA's extensive healthcare network with $112 billion annual healthcare spending
- Potential for significant sales growth from current <1% VA sales level
- Access to 171 VAMCs, 1,100+ outpatient facilities, and 700 Military Treatment Facilities
- Current VA sales represent less than 1% of total sales
Insights
This strategic partnership represents a significant market expansion opportunity for Zynex. The VA's
The timing is particularly opportune given the increasing focus on non-opioid pain management solutions in healthcare. With 9 million enrolled veterans in the VA system, even capturing a small market share could meaningfully impact Zynex's revenue. For a company with a market cap of
This partnership aligns perfectly with the VA's ongoing initiatives to address chronic pain management while reducing opioid dependency among veterans. The VA healthcare system's extensive reach and integrated structure could accelerate adoption of Zynex's non-invasive medical devices. The ability to access both VAMCs and MTFs creates a comprehensive distribution channel that covers both veteran and active military populations.
The administrative framework for VA partnerships typically ensures steady, reliable payment processes and long-term relationships, which could provide Zynex with stable revenue streams. The company's full product suite approach positions them well to address diverse pain management needs across this large patient population.
VA Spending on Hospital and Medical Care Exceeds
It is estimated that the VA spends over
With 171 VAMCs and over 1,100 outpatient facilities nationwide, the Department of Veterans Affairs serves millions of veterans annually. Additionally, there are approximately 700 Military Treatment Facilities (MTFs) operated by the Department of Defense, forming an extensive network for addressing the healthcare needs of service members and their families.
"Our partnership to do business with the VA represents a significant milestone in expanding access to non-opioid pain management solutions for those who have served our country," said Thomas Sandgaard, CEO, Founder, and Chairman. "Working with the VA provides us with access to the largest healthcare network in
As part of this collaboration, Zynex's sales team will work closely with healthcare providers within the VA and MTF networks to deliver its full product suite of innovative, pain management treatments designed to improve patient outcomes while addressing the unique pain management needs of these populations.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the safe harbor provisions of the
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2023 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.
Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contact:
Brian Prenoveau, CFA
MZ Group – MZ North America
ZYXI@mzgroup.us
+561 489 5315
View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-announces-partnership-to-conduct-business-with-veterans-affairs-va-medical-centers-the-largest-healthcare-network-in-the-united-states-302333802.html
SOURCE Zynex, Inc.
FAQ
What is the size of the VA healthcare market that ZYXI can now access?
What percentage of ZYXI's current sales come from VA Medical Centers?
How many VA facilities will ZYXI have access to through this partnership?
What products will ZYXI offer to VA Medical Centers?
